The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of dose-escalated alectinib in patients with metastatic ALK-positive NSCLC and CNS relapse on standard dose alectinib.
 
Justin Matthew Cheung
No Relationships to Disclose
 
Jiyoon Kang
No Relationships to Disclose
 
Beow Y. Yeap
Consulting or Advisory Role - Guardant Health (I)
Research Funding - Mercy BioAnalytics (I)
 
Jenn Peterson
No Relationships to Disclose
 
Andrew Do
No Relationships to Disclose
 
Subba R Digumarthy
Honoraria - Elsevier; Siemens
Speakers' Bureau - Siemens
Research Funding - Lunit; QURE AI; Vuno
Other Relationship - Abbvie; Anali; Bayer; BeiGene; Bristol-Myers Squibb; Cascadian Therapeutics; Gradalis; Merck; Novartis; Pfizer; Polaris; Resonance; Roche; Zai Lab
 
Justin F. Gainor
Employment - Ironwood Pharmaceuticals (I)
Stock and Other Ownership Interests - Ironwood Pharmaceuticals (I)
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Gilead Sciences; ITeos Therapeutics; Jounce Therapeutics; Karyopharm Therapeutics; Lilly; Loxo; Merck; Moderna Therapeutics; Oncorus; Regeneron; Takeda
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Bayer; Blueprint Medicines; C4 Therapeutics; Elevation Oncology; Genentech; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Regeneron; Turning Point Therapeutics
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer